Literature DB >> 3578451

Overview of the efficacy of hormonal replacement therapy.

B Ettinger.   

Abstract

The most widely recognized reason for prescribing estrogen for menopausal women is for control of symptoms. Estrogen effectively reduces the vasomotor, somatic, and associated psychologic components of the menopausal syndrome. Recently, however, the role of estrogen in the prevention of disease, particularly osteoporosis, urogenital atrophy, and atherosclerotic cardiovascular disease, has prompted consideration of this treatment for a more long-term goat. Bone loss occurring after menopause can be prevented by the use of estrogen; this significantly reduces the morbidity and mortality of associated fractures. Atrophic changes, which can occur earlier in the menopause than previously recognized, also respond to estrogen treatment. Atherosclerotic risk profiles are improved by estrogen replacement: blood pressure is lowered, total cholesterol and low-density lipoprotein cholesterol are reduced, and high-density lipoprotein cholesterol is increased. Most studies have found that the incidence of angina or myocardial infarction is lower in estrogen users than in nonusers, and overall mortality rates from cardiovascular disease appear to be reduced as well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578451     DOI: 10.1016/0002-9378(87)90168-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

Review 1.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

2.  Initiation and discontinuation of hormone therapy for menopausal symptoms: results from a community sample.

Authors:  Hayden B Bosworth; Lori A Bastian; Steven C Grambow; Colleen M McBride; Celette Sugg Skinner; Laura Fish; Barbara K Rimer; Ilene C Siegler
Journal:  J Behav Med       Date:  2005-02

Review 3.  Alternative strategies for prevention of postmenopausal osteoporosis.

Authors:  R Lindsay
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

4.  Lack of any estrogenic effect of ipriflavone in postmenopausal women.

Authors:  G B Melis; A M Paoletti; A Cagnacci; L Bufalino; A Spinetti; M Gambacciani; P Fioretti
Journal:  J Endocrinol Invest       Date:  1992-11       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.